Medici Brands Raises $250M to Build a Food Platform

Medici Brands announced a $250M Series B on September 2, 2026, to expand its portfolio of consumer food businesses and build the infrastructure required to launch more of them. Existing investors Greenoaks and Valor Equity Partners co-led the financing, with CEO Peter Rahal, ICONIQ, and Imaginary Ventures participating.

The transaction matters because Medici is no longer financing one fast-growing protein brand. It is financing a parent-company model that combines consumer brands, ingredient technology, retail distribution, product development, and shared operating infrastructure. The central question is whether the speed behind David Protein can become a repeatable system across candy, snacks, and future categories without turning every product into the same idea under another label.

What Happened

The company's announcement identifies Greenoaks and Valor as co-leads and names Peter Rahal, ICONIQ, and Imaginary Ventures as participants. Axios reported a $2.25B post-money valuation, although Medici did not disclose a valuation in its own release. The company also did not publish ownership terms, board changes, or the allocation among investors.

The Series B follows a $10M seed round for David in August 2024 and a $75M Series A in May 2025. Those publicly disclosed rounds bring the simple seed-to-Series-B total to $335M. A Form D filed in August reports different offering figures that do not reconcile transparently with the public announcement, so those numbers should not be added to the round total or treated as a second financing without further explanation.

Medici says the new capital will expand HallPass retail distribution and product development, extend David into new formats and categories, advance product innovation, and build the infrastructure required to launch brands including Rowdy. That is a wider mandate than scaling a single product line. It puts the parent company itself, and its ability to repeat product creation, on trial.

From David Protein to Medici Brands

David Protein launched direct-to-consumer in September 2024 with a flagship bar containing 28g of protein, 150 calories, and 0g of sugar. Medici says David now sells through more than 35,000 retail locations, including Walmart, Target, and Costco, and is on track to exceed $300M in 2026 revenue. Those growth figures are company-reported rather than independently audited, but they show why investors are underwriting a broader platform so quickly.

David has already expanded beyond bars into frozen dessert and ready-to-drink shakes. The company also experimented with other protein formats, including cod, which illustrates both the ambition and the limits of brand extension. A brand can stretch only so far before a new customer, category, price point, or retail occasion needs a separate identity.

That is the logic behind Medici. The parent organization, previously called Linus Technology, adopted the Medici name as Peter Rahal widened the operating plan beyond David. The portfolio now includes David, confectionery brand HallPass, and ingredient-technology company Epogee. Medici says another consumer brand, Rowdy, is planned for later in 2026.

Why Epogee Changes the Operating Model

David used a substantial portion of its $75M Series A to acquire Epogee, developer of EPG, a plant-based fat system used to preserve fat-like taste and texture while reducing absorbed calories. Food-industry reporting described the acquisition as both a supply-chain decision and a product-development decision. David was consuming a large share of Epogee's available capacity, and owning the supplier reduced dependence on a critical input.

The acquisition also gave Medici a deeper formulation layer. A food brand normally buys ingredients and builds products around them. Medici now owns a company behind one of the ingredients central to its product thesis. That can create speed and differentiation, but it also adds manufacturing, supply, regulatory, customer-access, and reputation responsibilities that a brand-only business can leave to a vendor.

Ingredient control is therefore not a magic moat. It is operating leverage with a maintenance bill. Medici must support its own brands, decide how Epogee serves outside customers, keep quality consistent, and expand capacity as more products depend on the same system. The $250M gives the company more room to build that layer, but it does not remove the complexity that ownership creates.

HallPass Tests the Portfolio Thesis

HallPass launched nationwide at Walmart in August 2026. Food Business News reported five initial stock-keeping units across peanut cups, peanut creme wafers, and chocolatey candy pieces, each positioned at 70 calories and 1g of sugar per package with a $1.82 price point.

The launch is strategically useful because HallPass is not simply a David flavor extension. It addresses a different buying occasion, competitive set, and price expectation while using formulation knowledge and EPG from the same corporate system. HallPass co-founder Michael Tierney has described the goal as creating a lower-calorie, lower-sugar competitor in a confectionery market dominated by Mars, Hershey, and Ferrero.

That turns HallPass into the first clean test of Medici's parent-company argument. If the shared infrastructure can help a distinct brand reach national retail quickly without making it feel derivative, Medici will have evidence that its operating model travels. If every new label depends too heavily on David's positioning, founder attention, or cultural heat, the portfolio may remain a collection of launches rather than a durable institution.

What the Investors Are Backing

Greenoaks and Valor previously invested in David's $75M Series A. Their decision to co-lead the Series B suggests they are underwriting the transition from a single brand to a multi-brand platform. Greenoaks partner Neil Shah framed Medici as a technology-enabled food platform, while Valor's Jon Shulkin emphasized the combination of consumer products and differentiated technology.

That investment thesis depends on more than product formulation. Medici must create repeatable capabilities across sourcing, manufacturing, packaging, retail relationships, inventory, customer research, regulatory work, marketing, and brand leadership. Some of those systems should be shared. Others must remain close enough to each brand that the portfolio does not become a corporate blur.

The tension is familiar in consumer markets. Centralization can make a company faster and more efficient, then slowly make its brands feel managed by the same committee. Medici's advantage will come from deciding what customers never need to see, and what each brand must protect as its own.

What This Signals for Consumer Food

The Series B is a large wager on an emerging structure in food: a venture-backed operating company that combines ingredient ownership with a portfolio of consumer brands. Traditional consumer conglomerates often assemble portfolios through acquisition. Medici is trying to build several of its brands from inside one shared system while moving at startup speed.

The company-reported results at David provide a strong opening record, but the next evidence will be less theatrical than a funding headline. HallPass must earn repeat purchases after its Walmart launch. David must preserve growth as it adds formats. Epogee must support a wider product map. Rowdy must arrive with a reason to exist beyond filling another shelf.

Medici now has enough capital to make those tests visible across several categories at once. Its future will be decided by whether formulation, distribution, and operating discipline can travel together while each brand keeps its own customer promise. The machinery will be shared. The shelf still judges every product separately.